Bunkerhill AVC vs Cardio-TriTest

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Bunkerhill AVC

by Bunkerhill Health

Cardio-TriTest

by Cardio-Phoenix Inc.

AI Verdict

While both tools aim to enhance cardiovascular disease detection through AI, they operate on fundamentally different principles. Bunkerhill AVC leverages generative AI to analyze existing chest CT scans for opportunistic detection and quantification of calcifications. In contrast, Cardio-TriTest is a dedicated device that combines ECG, PCG, and MCG to provide real-time, AI-powered analysis of heart bio-signals for earlier detection in primary care settings.

Choose Bunkerhill AVC if…

Choose Bunkerhill AVC if your health system aims to leverage existing chest CT imaging data for opportunistic screening and early detection of cardiovascular risks and bone density issues. This tool is ideal for integrating automated AI-driven analysis directly into your EHR workflows, enhancing efficiency and identifying conditions like aortic valve calcification without requiring additional dedicated scans.

View Bunkerhill AVC →

Choose Cardio-TriTest if…

Choose Cardio-TriTest if your primary care clinic or internal medicine practice requires a comprehensive, non-invasive diagnostic device for real-time cardiovascular disease detection. This 3-in-1 system is best suited for performing dedicated patient assessments, synchronizing ECG, PCG, and MCG data to provide a more holistic view of heart health at the point of care.

View Cardio-TriTest →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Bunkerhill AVC	Cardio-TriTest
Pricing	Unknown	Contact for pricing
Deployment	Unknown	Clinical setting (device-based)
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Bunkerhill AVC

Bunkerhill's Carebricks platform, which includes Bunkerhill AVC, offers deep integration with existing EHRs and clinical archives, allowing clinicians to interact with patient records using natural language through Carebricks Chat. This software-based approach, along with customizable AI agents, streamlines workflows directly within familiar systems, reducing the need for new hardware or separate data entry.

Clinical Value

Tie

Both tools demonstrate strong clinical value with FDA clearances. Bunkerhill AVC opportunistically detects and quantifies multiple cardiovascular conditions and bone density from existing CT scans, maximizing the utility of already acquired data. Cardio-TriTest (Cardio-HART) provides comprehensive, multi-modal cardiac diagnostics at the point of care, offering 'echo-level insight' for a broad range of cardiac conditions, which is critical for primary care settings.

Pricing & Value

Bunkerhill AVC

While both require direct contact for pricing, Bunkerhill Health has secured a national CMS reimbursement pathway (billing code G0680) for its AI-enabled cardiovascular analysis on CT scans, effective April 1, 2026. This provides a clear financial framework and significantly de-risks adoption for health systems, offering a more transparent path to return on investment compared to Tool B's more general statement about reimbursement in 'several regions'.

Enterprise Readiness

Bunkerhill AVC

Bunkerhill's Carebricks platform is designed for deep integration within large health systems, offering real-time read-and-write capabilities within EHRs and a no-code platform for building custom AI agents across various workflows. Its deployment at major institutions like Mayo Clinic and comprehensive security and business continuity plans demonstrate a higher level of enterprise readiness.

Innovation

Bunkerhill AVC

Bunkerhill's use of generative AI for clinical reasoning, natural language processing (Carebricks Chat), and a no-code platform for creating customizable AI agents represents a more advanced and flexible application of AI in healthcare. This approach moves beyond diagnostic analysis to intelligent interaction, workflow automation, and decision support across the entire patient record.

Support & Docs

Tie

Neither the provided structured facts nor the web search results offer sufficient specific details about the availability, quality, or scope of user-facing support and documentation for either tool. While some general company information and FAQs are available, explicit support structures or comprehensive documentation are not detailed for either product.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Bunkerhill AVC	Cardio-TriTest
Name	Bunkerhill AVC	Cardio-TriTest
Company	BunkerHill Health	Cardio-Phoenix Inc.
Description	FDA-cleared algorithm for early detection and quantification of aortic valve calcification from chest CTs, part of a generative AI platform for clinical reasoning and action.	AI-powered 3-in-1 diagnostic device combining ECG, PCG, and MCG to synchronize and visually correlate heart bio-signals for earlier and more comprehensive cardiovascular disease detection in primary care.
Primary Function	Automated detection and quantification of various calcifications (aortic valve, coronary artery, mitral annular) and opportunistic bone density assessment from CTs, with generative AI for clinical reasoning.	3-in-1 diagnostic device (ECG, PCG, MCG) for synchronized bio-signal acquisition and AI-powered analysis for heart disease detection.
Key Features (Partial)	Generative AI for clinical reasoning and action, Automated detection and quantification of aortic valve calcification (Bunkerhill AVC), Automated detection and quantification of coronary artery calcification (iCAC, Contrast CAC), Automated detection and quantification of mitral annular calcification (Bunkerhill MAC), Opportunistic bone density assessment (Bunkerhill BMD)	3-in-1 diagnostic device (ECG, PCG, MCG), 12-Lead Electrocardiograph (ECG), 4 Lead Phonocardiograph (PCG), 4 Lead Mechanocardiograph (MCG), Synchronized bio-signal acquisition

Videos

Demos, reviews, and walkthroughs featuring Bunkerhill AVC and Cardio-TriTest.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows, and what are the primary clinical scenarios where each tool provides the most value?

Bunkerhill AVC integrates into existing radiology workflows by analyzing routine chest CTs to opportunistically detect and quantify aortic valve calcification, coronary artery calcification, mitral annular calcification, and bone density, then coordinating follow-up care within the EHR. Cardio-TriTest, a device-based solution, introduces a new non-invasive diagnostic procedure in primary care settings, combining ECG, PCG, and MCG to provide a comprehensive cardiovascular assessment.

What is the depth of EHR integration for each tool, specifically regarding automated documentation, data flow into patient charts, and potential for clinical decision support within the EHR interface?

Bunkerhill AVC's Carebricks platform integrates with full EHRs and clinical archives, using natural language processing for patient record interaction and enabling customizable AI agents to automate tasks like initiating referrals, coordinating follow-up care, sending notifications, and placing orders. Cardio-TriTest acquires and records three types of heart bio-signals, combining the results into a contiguous presentation as an aid to diagnostic interpretation by a physician in a clinical setting, but the depth of its automated data flow into EHRs or direct clinical decision support within the EHR interface is not specified beyond aiding physician interpretation.

What specific accuracy, sensitivity, and specificity metrics are available for the AI algorithms in each tool, and how have these been validated across diverse patient populations?

Bunkerhill AVC's performance for aortic valve calcification detection and quantification was validated in a stand-alone retrospective study across 33 sites in the United States, demonstrating a low bias in Agatston-equivalent score, with an observed precision of 0.826 and recall of 0.855. Cardio-TriTest's AI-powered analysis for heart disease detection is supported by clinical validation of Cardio-HART (a related system by Cardio-Phoenix Inc.) across over 15,000 patients, showing greater than 90% sensitivity for heart failure and high rule-out safety (NPV > 97%), with consistent diagnostic performance across major cardiac disease families in diverse patient populations.

What is the estimated learning curve for physicians and clinical staff to proficiently use each tool, and what is the typical timeframe to realize significant clinical and operational benefits?

Bunkerhill AVC integrates into existing imaging workflows, with its Carebricks platform designed to deploy AI agents rapidly, potentially enabling health systems to design, test, and deploy AI agents in days, suggesting a relatively quick time-to-value for operational benefits by reducing manual work and improving patient care. Cardio-TriTest is a device-based diagnostic tool that combines ECG, PCG, and MCG, and while it aims to make heart health assessment easier for general practitioners by synchronizing and visually correlating bio-signals, specific details on the learning curve for operating the device and interpreting its AI-powered analysis, or the typical time-to-value, are not provided.

What are the key considerations for implementing and scaling each tool across multiple clinical sites or departments, and what level of ongoing technical and clinical support is provided?

Bunkerhill Health's Carebricks platform is designed for health systems to build and deploy AI agents across the enterprise, with existing programs in over 10 health systems and collaborations with academic medical centers for algorithm development and validation across diverse clinical environments, suggesting capabilities for multi-site rollout and support. Cardio-TriTest is a device intended for use in a clinical setting, but information regarding multi-site rollout considerations, scalability across departments, or the specifics of ongoing technical and clinical support is not detailed in the provided facts.

Beyond standard compliance, what advanced security features protect patient data, and what audit-trail capabilities are available to track AI-generated insights, user interactions, and diagnostic results?

Bunkerhill Health employs robust security measures including encryption of sensitive customer data at rest, annual penetration testing, and restricted privileged access to encryption keys, production applications, databases, and networks. Its platform also supports audit trails for user actions, system events, and AI model details, with logs secured using tamper-proof technologies and maintained for regulatory periods. Cardio-TriTest maintains detailed audit trails of user activities within its platform, enhancing accountability and demonstrating compliance with regulatory requirements regarding data access and usage, and protects data in transit and at rest through robust encryption protocols.

How do the target specialties and patient populations differ for Bunkerhill AVC's opportunistic CT-based screening versus Cardio-TriTest's device-based primary care cardiovascular assessment?

Bunkerhill AVC is primarily targeted at Cardiology and Radiology specialties, focusing on patients aged 40 and above who undergo routine chest CT scans for other indications, opportunistically identifying cardiovascular risks like aortic valve calcification. Cardio-TriTest is designed for Cardiology, Family Medicine, and Internal Medicine, serving as a non-invasive diagnostic aid for general practitioners in a clinical setting to assess cardiovascular health in males and females aged 20 years and above, not intended for pediatrics or intensive care units.